Tennor Therapeutics
Specializes in research and development of new drugs for the treatment of digestive diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 Valuation: €0.0 | round | |
* | $42.2m | Series E | |
| Total Funding | 000k | ||
Related Content
TenNor Therapeutics is a biotechnology company specializing in the development of innovative antibiotic treatments for complex infections. The company primarily serves healthcare providers and medical institutions, focusing on addressing unmet medical needs in the treatment of anaerobic pathogens and periprosthetic joint infections. Operating in the global pharmaceutical market, TenNor leverages advanced research and development to create novel antibiotic conjugates, such as oxazolidinone nitroimidazole, which have shown synergistic activity against difficult-to-treat infections. The business model revolves around the development and commercialization of these specialized antibiotics, generating revenue through product sales, licensing agreements, and collaborations with other pharmaceutical companies. TenNor's strategic partnerships with renowned institutions like the Mayo Clinic further bolster its research capabilities and market reach.
Keywords: biotechnology, antibiotics, anaerobic pathogens, joint infections, pharmaceutical, research, development, healthcare, innovation, partnerships.